Navigation Links
VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor
Date:1/31/2014

Leuven/Gent (Belgium), 31 January 2014 VIB and CD3 (KU Leuven) today announced the signing of a license and collaboration agreement with AstraZeneca for the development of novel MALT1 inhibitors as therapeutics in inflammatory and oncological diseases.

The research teams of Thijs Baens and Peter Marynen (VIB-KU Leuven, Center for Human Genetics) and Rudi Beyaert (VIB-UGent, Inflammation Research Center) were among the first to identify MALT1, an important regulator of the NF-κB signaling pathway and demonstrate its proteolytic activity on some key substrates. Since then, the proteolytic activity of MALT1 has emerged as a promising target for treatment of auto-immune disorders and certain types of cancer. VIB and CD3 launched a joint early drug discovery collaboration to identify small molecule MALT1 protease inhibitors, which now results in a license to AstraZeneca.

AstraZeneca aims to further develop the small molecule MALT1 inhibitors and, as part of the deal, the parties will join forces in an R&D collaboration to further investigate this interesting target. Both teams will undertake work outlined in the joint research plan .

Under the terms of the agreement, AstraZeneca will make an upfront payment and milestone payments based upon the achievement of development and regulatory goals. VIB and CD3 (KU Leuven) are eligible to receive royalty payments on future products developed under the agreement.

Johan Cardoen, Managing Director of VIB commented "We are very pleased with this license deal and strategic collaboration, bringing together top biological research, industry-standard early drug development and, now, a top notch industrial partner like AstraZeneca to give the program the best possible chances of success. This deal illustrates the potential of translating excellence-driven biological research into actual therapies for patients in need."

"It is great to see that the combination of the important academic research of VIB with the strengths and capabilities of CD3 has been fruitful and resulted in this license and collaboration with AstraZeneca", said Patrick Chaltin, Managing Director of CD3 at KU Leuven. "This agreement again emphasizes the strength and value of CD3's model as an investment fund and technology transfer platform for innovative drug discovery."

"This collaboration is a further example of our ambition to increase innovation by bringing together the best of academia and AZ science. We are confident that these joint efforts will increase our understanding of MALT1 and its role in autoimmunity and oncology, with the aim of discovering and developing more effective patient treatments", says Maarten Kraan, Vice President, Respiratory, Inflammation & Autoimmunity Innovative Medicines and Early Development unit, AstraZeneca Mlndal.


'/>"/>

Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-473-783-435
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. UK establishes 3 new synthetic biology research centers
2. £3m drug safety center investment
3. FAK helps tumor cells enter the bloodstream
4. Museum bird DNA ready for use in Naturalis Biodiversity Center
5. Eurofins and Orion Diagnostica Oy enter into an agreement on Orions proprietary SIBA technology
6. Uganda Heart Institute physicians and nurses visit Texas Childrens Heart Center
7. Army renews bio-inspired engineering and science research center at UC Santa Barbara with $48 million
8. Data centers can be cooled down in environmentally friendly, energy efficient ways
9. DFG establishes 9 new collaborative research centers
10. Wilson Center awarded European Union grant for synthetic biology work
11. Wake Forest Baptist Medical Center and Cornerstone Health Care Join in Unique Affiliation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 /PRNewswire/ ... facilities are primarily focused on medical screening ... measure point-of-care parameters. Wearable devices that facilitate ... user,s freedom of movement are being bolstered ... for human biomedical signal acquisition coupled with ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
Breaking Biology Technology: